Evaluate the Efficacy and Safety of DWP05195 in Subjects With Post-Herpetic Neuralgia

The Clinical Trial for Evaluation of Efficacy and Safety of DWP05195 in Postherpetic Neuralgia: Double-blind, Placebo-controlled, Randomized, Multi-center, Exploratory Clinical Trial

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01557010

Enrollment

140

Registered

2012-03-19

Start date

2012-03-31

Completion date

2013-12-31

Last updated

2014-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postherpetic Neuralgia

Brief summary

The purpose of this study is to evaluate efficacy, safety of administered DWP05195 in Postherpetic Neuralgia.

Interventions

DRUGDWP05195

Tablets, oral administration, 100mg

DRUGControl

Tablets, oral administration, Placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Male or Female subjects aged 20 to 80 years * Subjects with symptoms of neuropathic pain associated with postherpetic neuralgia(PHN). * Subjects must have pain present for \> 3 months after healing of the acute herpes zoster skin rash.

Exclusion criteria

* Other severe pain that may potentially confound pain assessment. * Subjects with symptoms of neuropathic pain applied Medical Equipment * Within 2 years: Subjects were diagnosed with cancer

Design outcomes

Primary

Measure	Time frame
Endpoint change from the baseline after administered 8 weeks mean pain score based on the Numerical pain Rating Scale(NPRS) from the subject's daily pain diary	8 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026